P. Giangrande

发表

Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection.

R. Phillips, P. Goulder, A. McMichael, 1996, AIDS research and human retroviruses.

Blood Products for Hemophilia

P. Giangrande, 2012, BioDrugs.

Plasma‐Derived Coagulation Factor Concentrates

P. Giangrande, 2010 .

Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven®) in children vs. adults with haemophilia A

P. Giangrande, G. Auerswald, M. Morfini, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Treatment of haemophilia in the United Kingdom 1981–1996

P. Giangrande, C. Rizza, R. Spooner, 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

Treatment of haemophilia in the United Kingdom 1981-1996.

P. Giangrande, C. Rizza, R. Spooner, 2001 .

Shaken baby syndrome

P. Giangrande, T. Jaspan, P. Richards, 2006, Archives of Disease in Childhood.

Gene therapy for hemophilia? No

P. Giangrande, 2004, Journal of thrombosis and haemostasis : JTH.

Mortality before and after HIV infection in the complete UK population of haemophiliacs

S. Darby, P. Giangrande, C. Rizza, 1995, Nature.

Thrombosis and air travel.

P. Giangrande, 2006, Journal of travel medicine.

The history of blood transfusion

P. Giangrande, 2000 .

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

P. Giangrande, J. Oldenburg, E. Santagostino, 2016, Thrombosis and Haemostasis.

Low‐factor consumption for major surgery in haemophilia B with long‐acting recombinant glycoPEGylated factor IX

P. Giangrande, R. Tehranchi, J. Mahlangu, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

40K glycoPEGylated, recombinant FVIIa: 3‐month, double‐blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors

P. Giangrande, R. Ljung, P. Arkhammar, 2013, Journal of thrombosis and haemostasis : JTH.

Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa)

P. Giangrande, J. Goudemand, C. Négrier, 2011, Journal of thrombosis and haemostasis : JTH.

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.

P. Giangrande, C. Négrier, A. Tiede, 2011, Blood.

Six Characters in Search of An Author: The History of the Nomenclature of Coagulation Factors

P. Giangrande, 2003, British journal of haematology.

The incidence of lymphoma in the UK haemophilia population between 1978 and 1999

S. Darby, A. Phillips, P. Giangrande, 2002, AIDS.

Quality‐of‐life differences between prophylactic and on‐demand factor replacement therapy in European haemophilia patients

P. Giangrande, B. Kroner, W. Schramm, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

FONDAPARINUX (ARIXTRA®): A NEW ANTICOAGULANT

P. Giangrande, P. Giangrande, 2002, The Medical letter on drugs and therapeutics.

ALA‐10 MUTATIONS IN THE FACTOR IX PROPEPTIDE AND HAEMORRHAGE IN A PATIENT TREATED WITH WARFARIN

P. Giangrande, D. Keeling, K. Clarke, 2000, British journal of haematology.

Ethnic variation in von Willebrand factor levels can influence the diagnosis of von Willebrand disease.

P. Giangrande, K. Sukhu, V. Poovalingam, 2003, Clinical and laboratory haematology.

Porcine factor VIII

P. Giangrande, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Detection of the prethrombotic state due to procoagulant imbalance

P. Mannucci, P. Giangrande, A. Bonomi, 1992, European journal of haematology.

Increased bleeding associated with protease inhibitor therapy in HIV‐positive patients with bleeding disorders

P. Giangrande, Christine A. Lee, C. Lee, 1999, British journal of haematology.

HEPATITIS IN HAEMOPHILIA

P. Giangrande, 1998, British journal of haematology.

Variant Creutzfeldt–Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty

P. Giangrande, J. Ironside, J. Ironside, 2005, Vox sanguinis.

nvCJD and Blood Products in the UK

P. Giangrande, 2006 .

Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.

S. Darby, P. Giangrande, Christine A. Lee, 2007, Blood.

Clinical outcomes and resource utilization associated with haemophilia care in Europe

P. Giangrande, B. Kroner, W. Schramm, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetics of Recombinant Factor VIII (Recombinate) Using One-stage Clotting and Chromogenic Factor VIII Assay

P. Giangrande, E. Gomperts, C. Hay, 1999, Thrombosis and Haemostasis.

Difficult clinical challenges in haemophilia: international experiential perspectives

P. Giangrande, E. Santagostino, C. Kessler, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Variation in inhibitor reactivity in acquired haemophilia A with different concentrates.

P. Giangrande, D. Keeling, K. Sukhu, 2000, Clinical and laboratory haematology.

Successful immune tolerance induction in two boys with haemophilia B and inhibitory antibodies

P. Giangrande, A. Klukowska, P. Laguna, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Treatment of Bleeding in FVIII Inhibitor Patients

P. Giangrande, J. Teitel, 2011 .

International recommendations on the diagnosis and treatment of acquired hemophilia A

P. Giangrande, V. Jiménez‐Yuste, C. Kessler, 2020, Haematologica.

Consensus perspectives on prophylactic therapy for haemophilia: summary statement

J. Astermark, P. Giangrande, R. Ljung, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors.

P. Giangrande, E. Santagostino, M. Ozelo, 2015, Blood reviews.

ORAL CARE FOR PEOPLE WITH HEMOPHILIA OR A HEREDITARY BLEEDING TENDENCY Second Edition

P. Giangrande, C. Scully, P. D. Dios, 2002 .

AIR TRAVEL AND THROMBOSIS

P. Giangrande, P. Giangrande, 2001, British journal of haematology.

Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders

F. Rosendaal, P. Giangrande, N. Özdemir, 2012, Journal of thrombosis and haemostasis : JTH.

Coagulation factor activity and clinical bleeding severity in rare bleeding disorders : results from the European Network of Rare Bleeding Disorders

F. Rosendaal, P. Giangrande, N. Özdemir, 2007 .

Adverse events in the prophylaxis of haemophilia

P. Giangrande, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

Pancreas allograft thrombosis.

P. Giangrande, P. Friend, A. Muthusamy, 2010, Transplantation.

Adverse outcome of human islet-allogeneic blood interaction1,2

P. Giangrande, A. Agarwal, L. Badet, 2003, Transplantation.

Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS

Martin A. Nowak, Robert A. Colbert, Sarah Rowland-Jones, 1997, Nature Medicine.

The interaction between primate blood and mouse islets induces accelerated clotting with islet destruction

P. Giangrande, E. Metzen, L. Badet, 2002, Xenotransplantation.

Two Neutropenic Patients with Multiple Resistant Pseudomonas Aeruginosa Septicaemia Treated with Ciprofloxacin

B. Azadian, P. Giangrande, D. Samson, 1987, Journal of the Royal Society of Medicine.

Treatment of patients with haemophilia and inhibitory antibodies

P. Giangrande, 2003, Indian journal of pediatrics.

History of Blood Transfusion

P. Giangrande, 2000, Nature.

Musculoskeletal problems in persons with inhibitors: How do we treat?

P. Giangrande, N. Goddard, K. Mulder, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Research in haemophilia B – approaching the request for high evidence levels in a rare disease

P. Giangrande, W. Schramm, R. Seitz, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Psychometric evaluation of a patient‐reported symptom assessment tool for adults with haemophilia (the HAEMO‐SYM)

P. Giangrande, J. Wasserman, A. Rentz, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Presentation of severe haemophilia—A role for accident and emergency doctors?

P. Giangrande, H. Minhas, 2001, Emergency medicine journal : EMJ.

Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia

S. Frostick, P. Giangrande, J. Thachil, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Haemophilia Care in Europe: the ESCHQoL study

L. Mantovani, M. Bullinger, A. Crispin, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Cost effectiveness of haemophilia treatment: a cross-national assessment

U. Siebert, P. Giangrande, W. Schramm, 2005, Blood Coagulation and Fibrinolysis.

Cost effectiveness of haemophilia treatment: a cross-national assessment

U. Siebert, P. Giangrande, W. Schramm, 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Perioperative management of haemophilia B: A critical appraisal of the evidence and current practices

E. Neufeld, P. Giangrande, D. Cooper, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

A cross‐over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate

P. Giangrande, K. Hampton, C. Lee, 1994, British journal of haematology.

Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates

P. Giangrande, P. Mannucci, W. Schramm, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates

P. Mannucci, P. Giangrande, P. Mannucci, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Resource utilisation in haemophiliacs treated in Europe: Results from the European Study on Socioeconomic Aspects of Haemophilia Care

P. Giangrande, C. Kessler, B. Kroner, 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical experience with a highly purified factor IX concentrate in patients undergoing surgical operations

P. Giangrande, G. Dolan, C. Lee, 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

factor IX : a first human dose trial in patients with hemophilia B Enhanced pharmacokinetic properties of a glycoPEGylated recombinant

P. Giangrande, C. Négrier, A. Tiede, 2011 .

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C

S. Darby, P. Giangrande, Christine A. Lee, 1997, The Lancet.

Title Page Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: A first human dose trial in patients with hemophilia B Running Title

P. Giangrande, C. Négrier, A. Tiede, 2017 .

Long‐term safety and efficacy of N8‐GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2

P. Giangrande, C. You, L. Nemes, 2020, Journal of thrombosis and haemostasis : JTH.

European principles of inhibitor management in patients with haemophilia

J. Blatny, P. Giangrande, C. Hermans, 2018, Orphanet Journal of Rare Diseases.

Uncovered needs in the management of inherited bleeding disorders in Italy.

L. Mantovani, P. Giangrande, L. Manzoli, 2014, Blood transfusion = Trasfusione del sangue.

Elective Orthopedic Surgery for Hemophilia Patients with Inhibitors

P. Giangrande, 2006 .

The economics of haemophilia prophylaxis: governmental and insurer perspectives. PROCEEDINGS OF THE SECOND INTERNATIONAL PROPHYLAXIS STUDY GROUP (IPSG) SYMPOSIUM

M. Bullinger, P. Giangrande, V. Blanchette, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Viral pharmacovigilance study of haemophiliacs receiving porcine factor VIII

P. Giangrande, C. Kessler, P. Webb, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Orthopedic management of patients with hemophilia in developing countries

P. Giangrande, 2011 .

Haemophilia B: Christmas disease

P. Giangrande, 2005, Expert opinion on pharmacotherapy.

Complications in HIV-infected and non-HIV-infected haemophiliacs and other patients after oral surgery.

P. Giangrande, C. Scully, P. Watt-Smith, 2002, International journal of oral and maxillofacial surgery.

Good dental care

P. Giangrande, A. Brewer, 2005, British Dental Journal.

The WFH Haemophilia Centre Twinning Programme: 10 years of growth, 1993–2003

P. Giangrande, G. Mariani, C. Black, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia.

P. Giangrande, T. Baglin, M. Makris, 2001 .

Present and future challenges in the treatment of haemophilia: the patient's perspective.

L. Mantovani, P. Giangrande, L. Manzoli, 2013, Blood transfusion = Trasfusione del sangue.

The European standards of Haemophilia Centres.

P. Giangrande, P. Mannucci, M. Makris, 2014, Blood transfusion = Trasfusione del sangue.

Management of haemophilia

P. Giangrande, 2011 .

The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands

P. Giangrande, D. Perry, A. Miners, 2016, European journal of haematology.

The Future of Hemophilia Treatment: Longer-Acting Factor Concentrates versus Gene Therapy

P. Giangrande, 2016, Seminars in Thrombosis & Hemostasis.

The Incidence of Factor VIII and Factor IX Inhibitors in the Hemophilia Population of the UK and Their Effect on Subsequent Mortality, 1977–991*

S. Darby, P. Giangrande, P. Collins, 2006 .

Symposium: haematologyManagement of haemophilia

P. Giangrande, 2015 .

Management of difficult‐to‐treat inhibitor patients

P. Giangrande, M. Escobar, Paul Giangrande, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

A postmarketing surveillance study of the safety and efficacy of ReFacto® (St Louis‐derived active substance) in patients with haemophilia A

P. Giangrande, R. Littlewood, J. Feingold, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

Making economic evaluations more helpful for treatment choices in haemophilia

P. Giangrande, U. Slothuus, M. Drummond, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement

P. Giangrande, V. Jiménez‐Yuste, G. Benson, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs.

P. Giangrande, P. G. Martin, K. Sukhu, 1998, Clinical and laboratory haematology.

European principles of inhibitor management in patients with haemophilia: implications of new treatment options

J. Astermark, J. Blatny, P. Giangrande, 2020, Orphanet Journal of Rare Diseases.

Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction

P. Giangrande, S. Misbah, D. Keeling, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

The molecular basis of hemophilia

P. Giangrande, 2019, Molecular Hematology 4e.

Products Used to Treat Hemophilia: Plasma‐Derived Coagulation Factor Concentrates

P. Giangrande, 2007 .

Hepatitis C and bleeding disorders in Europe

P. Giangrande, G. Dusheiko, R. Kaczmarek, 2018, The Journal of Haemophilia Practice.

Hepatitis C and bleeding disorders in Europe CLINICAL PRACTICE

P. Giangrande, G. Dusheiko, R. Kaczmarek, 2018 .

Glad tidings for haemophilia B patients

P. Giangrande, 2015 .

World Federation of Haemophilia programs in developing countries.

P. Giangrande, C. Black, 2005, Seminars in thrombosis and hemostasis.

Clotting factors VIII and IX

P. Giangrande, G. Brownlee, 2001 .

Safety and efficacy of KOGENATE® Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs)

P. Giangrande, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

The impact of HIV on mortality rates in the complete UK haemophilia population

S. Darby, C. Sabin, P. Giangrande, 2004, AIDS.

Two chimaeric transcription units result from an inversion breaking intron 1 of the factor VIII gene and a region reportedly affected by reciprocal translocations in T-cell leukaemia.

P. Green, P. Giangrande, F. Giannelli, 1996, Human molecular genetics.

PREGNANCY IN WOMEN WITH INHERITED BLEEDING DISORDERS

P. Giangrande, 2003 .

Choice of replacement therapy for hemophilia: recombinant products only?

P. Mannucci, P. Giangrande, 2000, The hematology journal : the official journal of the European Haematology Association.

Advances in the therapy of von Willebrand disease

P. Giangrande, J. Batlle, M. López-Fernández, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Treatment of hemophilia: recombinant factors only? Yes

P. Giangrande, 2003, Journal of thrombosis and haemostasis : JTH.

Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia

P. Giangrande, T. Baglin, M. Makris, 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

Choice of replacement therapy for hemophilia—cryoprecipitate issues: a rebuttal

P. Giangrande, A. Farrugia, 2004, Journal of Thrombosis and Haemostasis.

SIX CHARACTERS IN S EARCH OF AN AUTHOR: T HE HISTORY O F T HE NOMENCLATURE OF C OAGULATION FACTORS

P. Giangrande, 2003 .

Afibrinogenemia: first identification of a splicing mutation in the fibrinogen gamma chain gene leading to a major gamma chain truncation

P. Giangrande, E. Santagostino, P. Mannucci, 2000 .

Primary Mantle Cell Lymphoma Cell Cultures Soluble Cd40 Ligand Induces Selective Proliferation of Lymphoma Cells In

P. Giangrande, E. Santagostino, P. Mannucci, 2022 .

Fibrin Sealant Reduces Blood Loss in Total Hip Arthroplasty

D. Murray, P. Giangrande, R. Crawford, 1999 .

Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants

Sarah Rowland-Jones, Susan Daenke, Andrew J. McMichael, 1994, Nature.

Immunogenic HIV variant peptides that bind to HLA-B8 can fail to stimulate cytotoxic T lymphocyte responses.

P. Klenerman, A. Edwards, P. Giangrande, 1995, Journal of immunology.

Patterns of Immunodominance in HIV-1–specific Cytotoxic T Lymphocyte Responses in Two Human Histocompatibility Leukocyte Antigens (HLA)-identical Siblings with HLA-A*0201 Are Influenced by Epitope Mutation

R. Phillips, P. Goulder, A. McMichael, 1997, The Journal of experimental medicine.

Bone marrow transplantation for adults and children with poor risk acute lymphoblastic leukaemia in first complete remission.

P. Giangrande, A. Barrett, R. Phillips, 1988, Bone marrow transplantation.

A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A.

K. Shianna, D. Goldstein, J. Goedert, 2013, Human molecular genetics.

Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors.

S. Rowland-Jones, J. Bell, A. McMichael, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Von Willebrand Factor Multimeric Assay in Acquired von Willebrand Disease Diagnosis: A Report of Experience from North Estonia Medical Centre

P. Giangrande, L. Joutsi-Korhonen, E. Laane, 2021, Journal of Laboratory Physicians.

Immunological effects of intermediate purity clotting factor concentrates: failure to affect lymphocyte activation in vivo

P. Giangrande, A. Goodall, P. Kernoff, 1993, British journal of haematology.

Air travel and thrombosis.

P. Giangrande, 2001, International journal of clinical practice.

Evaluation of the von Willebrand factor antigen (vWF-Ag) assay using an immuno-turbidimetric method (STA Liatest vWF) automated on the MDA 180 coagulometer.

P. Giangrande, D. Keeling, P. G. Martin, 2000, Clinical and laboratory haematology.

Air travel and thrombosis: what about women on HRT?

P. Giangrande, 2001 .

Menorrhagia

P. Giangrande, K. Robinson, 2001, British medical journal.

Retrospective Neuropathological Review of Prion Disease in UK Haemophilic Patients

M. Esiri, P. Giangrande, Christine A. Lee, 1998, Thrombosis and Haemostasis.

Adverse Effects of Treatment with Porcine Factor VIII

P. Giangrande, E. Santagostino, A. Gringeri, 1991, Thrombosis and Haemostasis.

lymphoblastic leukemia ( ALL ) : analysis of cytogenetic data from Karyotype is an independent prognostic factor in adult acute

S. Darby, P. Giangrande, Christine A. Lee, 2007 .

Truncation Fibrinogen Gamma Chain Gene Leading to a Major Gamma Chain Afibrinogenemia: First Identification of a Splicing Mutation in The

P. Mannucci, P. Giangrande, E. Santagostino, 2022 .

Clinical Trials and Observations

L. Staudt, A. Rosenwald, W. Chan, 2007 .

The airline passenger: current medical issues.

Anthony N Nicholson, P. Giangrande, A. Nicholson, 2003, Travel medicine and infectious disease.

Haemophilia care in Europe: a survey of 19 countries

P. Giangrande, L. Prihodova, D. Noone, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Safe application of a 13-Gy split dose total body irradiation schedule prior to bone marrow transplantation.

P. Giangrande, P. Revell, R. Phillips, 1988, Bone marrow transplantation.

Symposium: haematologyManagement of haemophilia

P. Giangrande, 2015 .

Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders

F. Rosendaal, P. Giangrande, N. Özdemir, 2012, Journal of thrombosis and haemostasis : JTH.

Porcine factor VIII

P. Giangrande, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.